Lilly's Zepbound® (tirzepatide) superior to Wegovy® …

Dec 4, 2024 · Participants using Zepbound lost 50.3 lbs (22.8 kg) and participants on Wegovy lost 33.1 lbs (15.0 kg) SURMOUNT-5 compared Zepbound, a dual GIP and GLP-1 receptor …

CouponFollow Extension

2%
OFF

Lilly's Tirzepatide Superior To Wegovy® (semaglutide) In Head-to …

2 weeks from now

Dec 4, 2024 · On average, tirzepatide led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. At 72 weeks, tirzepatide was superior to Wegovy on both the primary endpoint …

lilly.com

47%
OFF

Lilly's Zepbound (tirzepatide) Superior To Wegovy (semaglutide) In …

2 weeks from now

Dec 5, 2024 · Zepbound (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy (semaglutide). On average, Zepbound led to a superior weight loss of 20.2% …

pharmajournalist.com

47%
OFF

Lilly's Zepbound Superior To Wegovy In Head-to-head Trial …

2 weeks from now

Dec 6, 2024 · Zepbound (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy (semaglutide). On average, Zepbound led to a superior weight loss of 20.2% …

pharmabiz.com

47%
OFF

Lilly's Zepbound® (tirzepatide) Superior To Wegovy® …

2 weeks from now

Dec 4, 2024 · Zepbound ® (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy ® (semaglutide). On average, Zepbound led to a superior weight loss of 20.2% …

prnewswire.com

47%
OFF

Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left

2 weeks from now

1 day ago · Disclosed positive topline results from Phase 3b SURMOUNT-5 study, showing that Zepbound (tirzepatide) provided 47% greater relative weight loss compared to Wegovy …

seekingalpha.com

47%
OFF

Lilly's Zepbound® (tirzepatide) Superior To Wegovy® …

2 weeks from now

Dec 4, 2024 · open-label randomized clinical trial. Zepbound ® (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy ® (semaglutide). On average, Zepbound led …

lilly.com

47%
OFF

Lilly's Zepbound® (tirzepatide) Superior To Wegovy® …

2 weeks from now

Dec 5, 2024 · Zepbound ® (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy ® (semaglutide). On average, Zepbound led to a superior weight loss of 20.2% …

biospace.com

2%
OFF

Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price …

2 weeks from now

2 days ago · Lilly has compared the effects of Zepbound and Wegovy in a head-to-head study, with Zepbound's 20.2% weight loss superior to Wegovy's 13.7%, so Novo is under some …

seekingalpha.com

$75
OFF

Novo Nordisk's Innovation Supports A Wide Moat And GLP-1

2 weeks from now

2 days ago · We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly …

morningstar.com

$3.53
OFF

LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy Of

2 weeks from now

1 day ago · Lilly’s most popular products are its tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound. Mounjaro recorded sales of $3.53 billion during the …

nasdaq.com

32%
OFF

Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market …

2 weeks from now

Tirzepatide and semaglutide have generated a total of ~$40bn in 2024, and both companies are forecasting significant revenue growth in 2025 — 32% for Lilly, and 20% for Novo at the …

seekingalpha.com